The treatment paradigms for B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are rapidly evolving. Fortunately, treatment options for CLL and MCL have expanded considerably in recent years thanks to an improved understanding of the molecular mechanisms underlying this disease. Bruton tyrosine kinase (BTK) inhibitors are one such treatment option. Although BTK inhibitors bring new hope to patients with CLL and MCL, the rapid introduction of these agents has also increased the complexity of treatment, making it challenging for hematologist/oncologists to incorporate these novel therapies into clinical practice. Given how quickly the use of BTK inhibitors in CLL and MCL treatment is evolving, it is difficult for even the most conscientious healthcare providers to stay up to date on advances.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.